Synergistic or additive effects of GA101 and cytotoxic drugs
| Mutation status/treatment . | Bortezomib . | Nutlin . | Fludarabine . | Chlorambucil . | Bendamustine . |
|---|---|---|---|---|---|
| M | |||||
| GA | A | A | A | A* | A* |
| GXL | A | A | A | A* | A |
| UM | |||||
| GA | Syn | A* | A | A* | A*** |
| GXL | Syn | A | A | A | A* |
| p53d | |||||
| GA | A | A** | A | A | A* |
| GXL | A* | A | A | A | A |
| Mutation status/treatment . | Bortezomib . | Nutlin . | Fludarabine . | Chlorambucil . | Bendamustine . |
|---|---|---|---|---|---|
| M | |||||
| GA | A | A | A | A* | A* |
| GXL | A | A | A | A* | A |
| UM | |||||
| GA | Syn | A* | A | A* | A*** |
| GXL | Syn | A | A | A | A* |
| p53d | |||||
| GA | A | A** | A | A | A* |
| GXL | A* | A | A | A | A |
Pooled results of 7 mutated (M), 5 unmutated (UM), and 3 p53-dysfunctional (p53d) patient samples treated with G or GXL in combination with different cytotoxic drugs.
A indicates additive trend; and Syn, synergistic trend; *0.1 < P < .05, **.01 < P < .05, and ***P < .001 for the statistically significant additive effect.